Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of FKC876 in relapsed/refractory indolent B-cell non-Hodgkin lymphoma
ChiCTR2200058587Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in mature B-cell lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Best objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2200058587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058587.